Tiotropium surpasses Ipratropium

Tiotropium significantly improves lung function, dyspnoea and quality of life in patients with chronic obstructive pulmonary disease (COPD) compared to alternative therapy.// Previous studies have suggested that tiotropium may be the only treatment other than smoking cessation capable of reversing ...

New research about chronic lung disease presented at CHEST 2008

...th open-label combinations of azelastine nasal spray, steroid nasal sprays, ipratropium nasal spray, or cromolyn nasal spray. The median duration of cough was 7 ye.... The most effective combination therapies were azelastine nasal spray with ipratropium and cromolyn sprays (73 percent) and azelastine nasal spray and intranasal ...

CHEST 2008: Featured abstracts

...th open-label combinations of azelastine nasal spray, steroid nasal sprays, ipratropium nasal spray, or cromolyn nasal spray. The median duration of cough was 7 ye.... The most effective combination therapies were azelastine nasal spray with ipratropium and cromolyn sprays (73 percent) and azelastine nasal spray and intranasal ...

News briefs: May issue of the journal Chest

... met the following criteria: (1) study patients were over the age of 35 with stable COPD; (2) intervention included inhaled LABAs vs placebo, inhaled ipratropium bromide, or inhaled tiotropium; (3) studies were of at least 4 weeks duration; and (4) primary outcomes included severe exacerbations, all-cause morta...

Watson Receives FDA Approval for Generic DuoNeb(R)

...on its Abbreviated New Drug Application (ANDA) for ipratropium Bromide and Albuterol Sulfate Inhalation Solution in the 0.5 mg/3 mg strength. Watson's ipratropium Bromide and Albuterol Sulfate product is the gener...g to IMS Health data. Watson intends to launch its ipratropium Bromide and Albuterol Sulfate product immediately....

Adult COPD or asthma could be effectively treated with Xopenex

... in intervals of 6 to 8 hours. This change was achieved with a 1.25 mg dose of Xopenex. In addition, the Xopenex group needed only 2.0 +/- 2.6 days of ipratropium bromide treatments. Patients receiving Xopenex were found to require significantly less nebulizer therapy and less adjuvant respiratory therapy, accor...